Skip to main content

Table 2 Differences in patients who had urine drug screen testing pre vs. post commercialization in Colorado, by hospital location

From: The impact of recreational marijuana commercialization on traumatic injury

 

Colorado hospitals

Non-Colorado hospitals

Covariate (%)

UDS performed Pre (n = 1027)

UDS performed

Post (n = 1013)

P value

UDS performed Pre (n = 1786)

UDS performed

Post (n = 1507)

P value

Age (years), mean

42.2

43.9

0.03

41.0

39.8

0.06

Male sex

69.9%

72.2%

0.26

67.4%

69.7%

0.15

Non-White race

28.1%

24.7%

0.08

23.7%

37.0%

< 0.001

Glasgow Coma score 3–8

17.2%

16.6%

0.74

17.7%

19.6%

0.16

Injury severity score, mean

12.8

12.7

0.87

11.5

11.4

0.95

SBP < 90 mmHg

5.0%

4.4%

0.53

3.5%

4.7%

0.08

Penetrating mechanism

7.2%

7.6%

0.85

8.7%

11.4%

< 0.001

Cause of injury

  

0.36

  

< 0.001

Motor vehicle crash

43.9%

40.4%

 

48.6%

49.4%

 

Fall

31.3%

33.0%

 

24.6%

20.6%

 

Sports related

7.6%

8.8%

 

3.5%

2.1%

 

Assault/Stab/GSW

14.8%

14.5%

 

11.5%

15.9%

 

Other

2.4%

3.4%

 

11.8%

11.9%

 

Full activation

44.3%

38.3%

< 0.001

38.8%

45.7%

< 0.001

ICU admission

53.4%

57.2%

0.08

53.6%

55.5%

0.27

Mortality

4.8%

4.7%

0.97

5.9%

5.1%

0.34

  1. Pre-commercialization, 2012–2013. Post-commercialization, 2014–2015. SBP systolic blood pressure, GSW gunshot wound, ICU intensive care unit. Bolding denotes p values that met the alpha < 0.05 significance level